[Cell Replacement Therapy in Parkinson's Disease-History of Development and Prospects for Use in Clinical Practice].
Parkinson's disease
cell differentiation
cell replacement therapy
embryonic stem cells
induced pluripotent stem cells
neuronal progenitors
Journal
Molekuliarnaia biologiia
ISSN: 0026-8984
Titre abrégé: Mol Biol (Mosk)
Pays: Russia (Federation)
ID NLM: 0105454
Informations de publication
Date de publication:
Historique:
received:
23
04
2020
accepted:
25
06
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years.
Identifiants
pubmed: 33276357
doi: 10.31857/S0026898420060063
doi:
Types de publication
Journal Article
Review
Langues
rus
Sous-ensembles de citation
IM